Centessa Pharmaceuticals (CNTA) Income towards Parent Company (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Income towards Parent Company of -$79.2 million for Q1 2026, down 203.2% year-over-year from $76.8 million in Q1 2025, and down 19.77% on a QoQ basis from -$66.2 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Income towards Parent Company data on file, last reported at -$79.2 million in Q1 2026.
- Quarterly Income towards Parent Company fell 203.2% year-over-year to -$79.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$250.6 million (down 11.97% YoY) and the FY2025 annual result came in at -$197.5 million, up 16.21% from the prior year.
- Income towards Parent Company declined to -$79.2 million in Q1 2026 per CNTA's latest filing, from -$66.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$24.9 million in Q2 2023 and bottomed at -$111.3 million in Q4 2024.
- The 5-year median for Income towards Parent Company is -$50.3 million (2025), against an average of -$51.8 million.
- The widest annual swing landed in 2022, when Income towards Parent Company jumped 77.17%; it then plunged 203.2% in 2026.
- Tracing CNTA's Income towards Parent Company over 5 years: stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then sank by 202.22% to -$111.3 million in 2024, then soared by 40.57% to -$66.2 million in 2025, then declined by 19.77% to -$79.2 million in 2026.
- Per Business Quant, the three latest CNTA Income towards Parent Company figures stand at -$79.2 million (Q1 2026), -$66.2 million (Q4 2025), and -$54.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.24 Mn |
| Dec 31, 2025 | -66.16 Mn |
| Sep 30, 2025 | -54.89 Mn |
| Jun 30, 2025 | -50.34 Mn |
| Mar 31, 2025 | -26.14 Mn |
| Dec 31, 2024 | -111.33 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -43.82 Mn |
| Mar 31, 2024 | -38.05 Mn |
| Dec 31, 2023 | -36.84 Mn |
| Sep 30, 2023 | -38.65 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -50.71 Mn |
| Dec 31, 2022 | -43.17 Mn |
| Sep 30, 2022 | -53.92 Mn |
| Jun 30, 2022 | -64.66 Mn |
| Mar 31, 2022 | -54.50 Mn |
| Dec 31, 2021 | -60.77 Mn |
| Sep 30, 2021 | -40.16 Mn |
| Jun 30, 2021 | -41.45 Mn |
| Mar 31, 2021 | -238.69 Mn |
| Dec 31, 2020 | -3.02 Mn |
| Sep 30, 2020 | -2.14 Mn |
| Jun 30, 2020 | -2.15 Mn |